An interventional study of Transcatheter valve replacement therapy in Severe Native Calcific Aortic Stenosis and Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis, sponsored by Abbott Medical Devices. Not yet recruiting at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment
Australia, France, Germany, Italy, Norway, Portugal, Spain, Sweden
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Aortic Valve Stenosis by Abbott — 4 open to participants now, 9 under way, none of them phase 3. Aortic Valve Stenosis · Abbott.
Among the 26 studies in Aortic Valve Stenosis by Abbott, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 19 with no phase, and was the 26th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →4 of the 26 studies in Aortic Valve Stenosis by Abbott are open now, in 12 countries. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Japan
Ages 18–100
Abbott Medical Devices · Sites in Australia, France, Germany and 8 more countries
Ages 18–100
Abbott Medical Devices · Sites in United States, Australia, Belgium and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 300 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 177 across the 20 interventional studies, 215 across the 6 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Abbott Medical Devices, one of the names counted as Abbott. Under that name alone:
Abbott Medical Devices is the lead sponsor of 541 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
3 of the studies in Aortic Valve Stenosis by Abbott that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT07082426Abbott Medical DevicesEarly System Experience With the Abbott Balloon-expandable TAVI System: First-In-Human Study | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Aortic Valve Stenosis by Abbott, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
VOYAGER CE Clinical Study using the Encantor TAVI System.
The VOYAGER CE trial is a prospective, single-arm, multi-center, pre-market clinical investigation designed to evaluate the safety and performance of the Encantor TAVI System. This clinical trial will enroll subjects who have symptomatic heart disease due to severe native calcific aortic stenosis and who are judged by a heart team to be appropriate for transcatheter valve replacement therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Encantor System is intended to treat patients with symptomatic severe aortic stenosis via transcatheter aortic valve implantation (TAVI)
Device: Transcatheter valve replacement therapy
This intervention is distinguished by the use of the Encantor TAVI System, a transcatheter valve replacement therapy specifically designed for patients with symptomatic severe native calcific aortic stenosis who are considered appropriate candidates by a multidisciplinary heart team. This device is intended to provide a minimally invasive alternative to surgical aortic valve replacement.
Composite of all-cause mortality or all strokes at 12 months post index
Composite of all-cause mortality or all strokes
Time frame: 12 months post index
Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 22 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Australia, France, Germany, Italy, Norway, Portugal, Spain, Sweden
Australia, France, Germany, Italy, Norway, Portugal, Spain, Sweden
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.